Cargando…

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136773/ http://dx.doi.org/10.1007/s40278-022-15735-7

Ejemplares similares

Safety of seven COVID-19 vaccine booster doses
Publicado: (2021)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

COVID-19 vaccination in the setting of mastocytosis—Pfizer-BioNTech mRNA vaccine is safe and well tolerated
por: Lazarinis, Nikolaos, et al.
Publicado: (2022)

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
por: Regev-Yochay, Gili, et al.
Publicado: (2022)

Safety of mRNA COVID-19 vaccines during pregnancy
Publicado: (2022)

Myocarditis rare after COVID-19 mRNA vaccination
Publicado: (2021)

mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks, and Coverage
por: Nashwan, Abdulqadir J., et al.
Publicado: (2022)

Abstract #1403045: Thyroiditis Post COVID-19 mRNA Booster Dose Vaccination
por: Seow, Cherng Jye
Publicado: (2023)

COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
Publicado: (2021)

Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines
Publicado: (2021)

mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)

No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine
Publicado: (2022)

Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines
Publicado: (2022)

mRNA-based vs viral vector-based COVID-19 vaccines
Publicado: (2021)

Humoral response to a fourth dose of mRNA vaccine in kidney transplant recipient responders to three doses of mRNA vaccine
por: de Nattes, Tristan, et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
por: Mengesha, Bethlehem, et al.
Publicado: (2022)

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
por: Grewal, Ramandip, et al.
Publicado: (2023)

Tolerance of the mRNA COVID-19 vaccines in patients with reported taxane reactions
por: Alenazy, Leila A., et al.
Publicado: (2022)

Cardiac risks higher after COVID-19 infection than mRNA vaccine
Publicado: (2022)

Imaging of Myocarditis Following mRNA COVID-19 Booster Vaccination
por: Sanchez Tijmes, Felipe, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination
Publicado: (2022)

Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed
Publicado: (2022)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
por: Rescigno, Maria, et al.
Publicado: (2023)

Humoral response after a fourth “booster” dose of a Coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients
por: Housset, Pierre, et al.
Publicado: (2022)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Booster Effect of a Third mRNA-Based COVID-19 Vaccine Dose in Patients with Myeloid Malignancies
por: Mori, Akio, et al.
Publicado: (2022)

Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
por: Grewal, Ramandip, et al.
Publicado: (2023)

Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization
por: AlOtaibi, Ibtihal, et al.
Publicado: (2023)

Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2023)

Acute myocarditis after the third dose of COVID‐19 mRNA‐1273 vaccine
por: Yamada, Takayuki
Publicado: (2023)

Myocarditis following COVID-19 mRNA vaccination
por: Parmar, Kanak, et al.
Publicado: (2021)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
por: Goldwater, Marissa-Skye, et al.
Publicado: (2023)

Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience()
por: Bertozzi, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cik93sdof2uj48grg6umnpceof